This Article Full Text Full Text (PDF) All Versions of this Article: 37/2/452    most recent 01.STR.0000198887.81948.74v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by O’Donnell, M. J. Articles by Sandset, P. M. Search for Related Content PubMed PubMed Citation Articles by O’Donnell, M. J. Articles by Sandset, P. M. Related Collections Anticoagulants Heparin Acute Cerebral Infarction Embolic stroke

(Stroke. 2006;37:452.)
© 2006 American Heart Association, Inc.

Original Contributions

Are There Patients With Acute Ischemic Stroke and Atrial Fibrillation That Benefit From Low Molecular Weight Heparin?

From the Stanford Stroke Center (M.J.O.), Stanford University Medical Center, Palo Alto, Calif; and Department of Hematology (E.B., P.M.S.), Ullevål University Hospital, Oslo, Norway.

Correspondence to Dr Eivind Berge, Department of Hematology, Ullevål University Hospital, N-0407 Oslo, Norway. E-mail eivind.berge{at}medisin uio.no

Background and Purpose— Treatment doses of heparins are not recommended for acute ischemic stroke. Despite this, their use in this setting is widespread. We investigated whether subgroups of patients with acute ischemic stroke and atrial fibrillation, identified by clinical, hemostatic (D-dimer, prothombin fragments₁₊₂ [F₁₊₂], soluble fibrin monomer), or inflammatory (C-reactive protein [CRP]) variables might have a differential response to low molecular weight heparin (LMWH) over aspirin. In addition, we sought to identify factors associated with a poor clinical outcome at 3 months.

Methods— We conducted a post hoc subgroup analysis of a randomized, placebo-controlled, double-blind trial (Heparin in Acute Embolic Stroke Trial) designed to test the hypothesis that treatment doses of LMWH (dalteparin; 100 IU/kg BID) would be superior to aspirin (160 mg per day) in patients with acute ischemic stroke and atrial fibrillation. For the current analysis, 431 participants were included. The primary outcome measure was a poor outcome at 3 months, defined as death or dependency in activities of daily living. Using regression analysis, we determined whether any of the chosen variables were associated with a differential response to dalteparin (treatment interaction) or with poor outcome.

Results— In the multivariable logistic regression model, none of the clinical, hemostatic, or inflammatory variables were associated with a significant treatment interaction. Stroke severity (odds ratio [OR], 1.09 [95% CI, 1.07 to 1.12]), increasing age (OR, 1.09 [CI, 1.05 to 1.14]), CRP level (OR, 1.32 [CI, 1.04 to 1.66]), and F₁₊₂ level (OR, 1.77 [CI, 1.07 to 2.91]) were independently associated with a poor outcome at 3 months.

Conclusions— Our study does not support the use of treatment doses of LMWH in any of the studied subgroups of patients with acute ischemic stroke and atrial fibrillation. Age, stroke severity, CRP, and F₁₊₂ were predictive of poor outcome at 3 months.

Key Words: heparin • stroke, ischemic • atrial fibrillation